Gilead Sciences (LTS:0QYQ) 3-Year FCF Growth Rate

: -0.30% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Gilead Sciences's Free Cash Flow per Share for the three months ended in Dec. 2023 was $1.56.

During the past 12 months, Gilead Sciences's average Free Cash Flow per Share Growth Rate was -10.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -0.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 1.60% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Gilead Sciences was 116.90% per year. The lowest was -68.40% per year. And the median was 4.80% per year.

Competitive Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences 3-Year FCF Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 3-Year FCF Growth Rate falls into.

Gilead Sciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Gilead Sciences (LTS:0QYQ) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Gilead Sciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (LTS:0QYQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (LTS:0QYQ) Headlines

No Headlines